PROTEMBIS-GMBH
15.9.2022 07:01:51 CEST | Business Wire | Press release
Protembis GmbH, a privately-held emerging cardiovascular medical device company, announced today the appointment of highly experienced and successful serial entrepreneur and medical device executive Azin Parhizgar (Ph.D.) as an Independent Member and Chairwoman of the Board of Directors.
Azin remains committed to the embolic protection field after her recent successes with Claret Medical. During her five years as President and CEO of Claret, she nurtured the company from its infancy to successful revenue generation with commercial sales in the U.S., Europe and other markets leading to a successful $270 million exit of the company to Boston Scientific Corporation.
Azin is currently also the Chairwoman of CVPath Institute, a Senior Venture Partner at 415 Capital, and a Board member at InnovHeart, CroíValve, Soundbite Medical Solutions, Moray Medical, among others. Prior to Claret Medical, Azin served as the COO of Conor Medsystems, which led to the acquisition of the company by Johnson & Johnson. Previously she held the position of Executive VP for Arterial Vascular Engineering (AVE), which was acquired by Medtronic. She spent two years at Medtronic post-merger expanding her roles and responsibilities leading to her position as Executive VP of Emerging Ventures and New Technologies. Azin received both her Ph.D. in Cell, Gene and Tissue Engineering and her M.Sc. in Biomechanical Engineering and Artificial Organ Design from Brown University.
“It is both exciting and an honor for us that Azin has chosen to lead our Board of Directors as new Chairwoman,” said Karl von Mangoldt and Conrad Rasmus, Co-CEOs of Protembis. “Azin continues to be committed to this space and brings incredible experience in the field of embolic protection and medical devices to Protembis. We are delighted to have Azin’s insights and strategic advice as we generate additional clinical data and advance the development of the ProtEmbo System.”
“I have watched Protembis’ successes and this space over the past years. I am convinced that there is a need for a simple and effective next generation complete cerebral protection system” notes Azin Parhizgar. “Protembis has developed an intuitive and differentiated technology, and I am very much looking forward to joining this great group of people to support the company’s continued success and value creation.”
Protembis plans to conduct an IDE study aimed at demonstrating safety and efficacy of the ProtEmbo® Cerebral Protection System (“ProtEmbo”) during transcatheter aortic valve replacement (“TAVR”). The ProtEmbo® System is an intra-aortic filter device that deflects embolic material away from the brain during TAVR. It is a low-profile system which is delivered through the left radial artery for optimal placement and stability. This is an ideal access site enabling physicians to avoid interference with TAVR equipment which is typically delivered through the femoral artery. The IDE study is designed as a multicenter randomized controlled trial in the USA and Europe.
About Protembis
Protembis is a privately-held emerging medical device company that has developed the ProtEmbo® Cerebral Protection System. The company strives to provide a simple and reliable solution to protect patients from brain injury during left-sided heart procedures, improving patient quality of life and reducing overall healthcare costs associated with brain injury during such procedures. The ProtEmbo® System is currently undergoing clinical investigations and has not yet been approved for commercial use by a regulatory authority.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914006022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cegid and Silae Join Forces to Create a European Leader in AI-Driven Business Technology9.9.2026 12:32:00 CEST | Press release
Planned Merger Enables Trusted, Fully Integrated Experience Across E-Invoicing, Accounting, Tax, Payroll and HR, Digital Financial Services and Payments for Businesses and their PartnersChristian Pedersen Joins Cegid as CEO to Lead Combined Group Cegid, an AI-driven European leader in cloud business management software for small and medium-sized businesses (SMBs), and accounting professionals, and Silae, France’s leading payroll and human resources platform, today announced their intention to merge. The combination will create a national technology champion and the leading European technology platform for businesses and their partners, helping them grow safely and efficiently with the support of a fully integrated and compliant suite covering their end-to-end financial and administrative needs. Between them, Cegid, following its recent acquisition of Shine, and Silae power the day-to-day accounting, tax, finance and payroll of 2 million end-customers and more than 15,000 chartered acco
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year9.9.2026 12:30:00 CEST | Press release
Notable additional benefit observed with an added reduction in MADRS1 score leading to an average 13-point reduction from baseline at Week 52 with durability extended out to 1 year for participants who were randomized to the 25 mg arm and received an additional doseFor participants randomized to Placebo arm who received first dose of COMP360 25 mg in open-label Part C, data further reinforces that a single 25 mg dose can produce rapid onset, meaningful effect and durabilityFor all participants in Part C who received a 25 mg open-label dose, strong response and remission rates were observed with 40%-45% responders2 and approximately 30% remitters3 across all timepoints 6 weeks post the Part C doseThis 1-year data further supports the belief that, if approved, COMP360 could establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a yearCOMP
New ABB and BCG Report Highlights Growing Role of Direct Current Technologies in Future Power Systems9.9.2026 11:42:00 CEST | Press release
Rapid expansion of AI computing, increasing electrification and rise of renewable energy are driving renewed interest in DC technology as part of future electrical systems Both AC and DC systems have strategically important roles in meeting future electricity demand Establishing common standards and developing DC-specific skills can help accelerate deployment ABB today published a new report, The Strategic Case for Hybrid AC/DC Power: Shaping the Transition to the Next Electrical Architecture, developed in collaboration with Boston Consulting Group (BCG). The report makes the case that direct current (DC) technology is moving from the periphery to the center of industrial, commercial, and digital infrastructure – and that the decisions made by business leaders and policymakers in the next two to three years will determine who shapes that transition and who inherits it. The future of power distribution is not an either-or choice between alternating current (AC) and direct current, but a
Visa and World Bank Group Announce New Risk-Sharing Initiative to Expand Digital Payments and Financial Inclusion in Emerging Markets9.9.2026 11:00:00 CEST | Press release
Visa (NYSE: V), a global leader in digital payments, and the International Finance Corporation (IFC), a member of the World Bank Group focused on the private sector, are partnering on an innovative risk-sharing initiative designed to help expand financial inclusion by increasing access to digital financial services in emerging markets. Under the agreement, IFC will share credit settlement risk for Visa transactions associated with enrolled financial institutions, enabling these institutions to connect more underbanked consumers and small businesses to digital payments. The facility is expected to support approximately $200 million in risk sharing over five years, with an initial focus on 14 countries in Latin America and the Caribbean and reach approximately 50 financial institutions with below-investment grade ratings. Together, Visa and IFC aim to help financial institutions enable millions more people and small businesses to save, spend, borrow, grow, and participate more fully in t
Chiesi Group Delivers Solid H1 2026 Performance, Combining Growth, Continued Investment in Innovation and Positive Economic Impact Across Communities9.9.2026 11:00:00 CEST | Press release
HIGHLIGHTS H1 2026 revenues of €1.89 billion, up +3.6% at CER versus H1 2025, driven by growth in the inhaled triple therapy portfolio and strong momentum in the rare diseases therapeutic area Continued investment in innovation with €426 million invested in R&D (22.5% of sales) Completed strategic investment for treatment of hereditary angioedema (HAE) with acquisition of KalVista Pharmaceuticals EBITDA continues to remain close to 30%, reflecting continued strong profitability and disciplined resource allocation Recent Economic Footprint study highlights Chiesi's contribution to economic development, supporting 56,488 jobs globally, generating €6.0 billion in GDP impact and €2.0 billion in taxes and public revenues worldwide Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical company and certified B Corp, today announced its financial results for the six months ended 30 June 2026 ("H1 2026"). Performance across therapeutic areas and regions Chiesi reported rev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom